Published in final edited form as:

Psychol Med. 2019 January ; 49(2): 243–249. doi:10.1017/S0033291718000661.

Reduced Immunity to Measles in Adults with Major Depressive Disorder

Bart N. Ford^{1,2}, Robert H. Yolken³, Faith B. Dickerson⁴, T. Kent Teague⁵, Michael R. Irwin⁶, Martin P. Paulus¹, and Jonathan Savitz^{1,7}

¹Laureate Institute for Brain Research, Tulsa, OK, USA

²The University of Tulsa Department of Biological Sciences, Tulsa, OK, USA

³Stanley Division of Developmental Neurovirology, Johns Hopkins University, Baltimore, MD, USA

⁴Sheppard Pratt Health System, Baltimore, MD, USA

⁵Departments of Surgery and Psychiatry, University of Oklahoma School of Community Medicine, Department of Biochemistry and Microbiology, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA

⁶Cousins Center for Psychoneuroimmunology at UCLA, Semel Institute for Neuroscience and UCLA David Geffen School of Medicine, Los Angeles, CA, USA

⁷Oxley College of Health Sciences, The University of Tulsa, Tulsa, OK, USA

Abstract

Background.—Depression can impair the immunogenicity of vaccine administration in adults. Whereas many vaccinations are administered in childhood, it is not known whether adolescent or adult onset depression is associated with impairments in maintenance of protection of childhood vaccines. This study tested the hypothesis that individuals with adolescent or adult onset mood disorders would display compromised immunity to measles, a target of childhood vaccination.

Methods.—IgG antibodies to measles were quantified using a solid phase immunoassay in volunteers with bipolar disorder (BD, n=64, mean age of onset=16.6±5.6), currently depressed individuals with major depressive disorder (cMDD, n=85, mean age of onset=17.9±7.0), remitted individuals with a history of MDD (rMDD, n=82, mean age of onset=19.2±8.6), and non-depressed comparison controls (HC, n=202), all born after the introduction of the measles vaccine in the USA in 1963.

Results.—Relative to HC, both the cMDD group (p=0.021, adjusted OR=0.47, CI=0.24–0.90) and the rMDD group (p=0.038, adjusted OR=0.50, CI=0.26–0.97) were less likely to test

Corresponding Author: Bart Ford, Laureate Institute for Brain Research and Department of Biological Sciences, The University of Tulsa, Tulsa, OK, USA, Ph: 918-607-8361, bford@laureateinstitute.org. **Alternate Corresponding Author:** Jonathan Savitz, Laureate Institute for Brain Research, Tulsa, OK, USA, Ph: 918-502-5104, jsavitz@laureateinstitute.org.

Financial Disclosures

The other authors have no disclosures.

Ethics Statement

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

seropositive for measles. Compared with unmedicated MDD participants, currently medicated MDD participants had a longer lifetime duration of illness and were less likely to test seropositive for measles.

Conclusions.—Individuals with adolescent or adult onset MDD are less likely to test seropositive for measles. Because lower IgG titers are associated with increased risk of measles infection, MDD may increase the risk and severity of infection possibly because of impaired maintenance of vaccine related protection from measles.

Keywords

Vaccine; Major Depressive Disorder; Measles; Infection; Stress; Depression

Introduction

Measles is a highly contagious viral illness that can result in encephalitis and death, thus reduction of vaccine coverage in a population can have serious public health consequences. Worldwide, measles remains a leading cause of death for young children despite ongoing immunization campaigns (*Measles Fact Sheet* 2017). Even in countries such as the USA, where vaccination has been tremendously successful in reducing the incidence of measles, outbreaks still occur (*Measles Cases and Outbreaks* n.d.). The national measles vaccine program was implemented in 1963 to combat the ~500,000 annual cases of measles in the United States (Fiebelkorn *et al.* 2010). The Advisory Committee on Immunization Practices currently recommends a two dose schedule for the measles, mumps, and rubella (MMR) or MMR-Varicella vaccine with one dose given at 12 to 15 months of age and the second administered at 4 to 6 years old, before entering school (McLean *et al.* 2013).

Given that natural measles exposure is rare in the USA, the absence of anti-measles antibodies in an individual can be a result of failure to receive immunization, failure to seroconvert after vaccination, or waning immunity subsequent to seroconversion. However, current MMR vaccination rates in the USA are 91.9% for children aged 19–35 months old and 94.2% for children entering kindergarten (Seither *et al.* 2016), and only about 5% of individuals vaccinated between the ages of 12 and 15 months fail to seroconvert (Redd *et al.* 2004). Furthermore, in those who seroconvert, the MMR vaccine-induced immunity to measles, mumps, and rubella is believed to be long lasting. Nevertheless, several studies have demonstrated that the levels of IgG antibodies decline over time, with one model estimating a decline of approximately 5% per annum in measles antibodies with a half-life of 12 years (Mossong *et al.* 1999). Consistent with these data, a twenty-year follow-up of 85 children who received MMR doses at 14–18 months old and 6 years old showed that 5% had lost detectable measles antibodies and 13% had equivocal levels of antibodies (Dine *et al.* 2004). Another study, using the more sensitive plaque reduction neutralization assay, found detectable measles antibodies in all 56 participants 26 to 33 years post vaccination, but 8% had titers below the level considered to be protective against infection (Davidkin *et al.* 2008). The factors contributing to this loss of immunity following the MMR are not completely understood.

Depression has been associated with impairment of viral specific cell-mediated immunity, and vaccine-stimulated immune responses. In a cross-sectional study of elderly community-dwelling adults enrolled in the shingles prevention study, subjects with current major depressive disorder (MDD) had a reduced T-cell response to varicella-zoster virus (VZV) compared with age and sex-matched controls (Irwin *et al.* 2011). Moreover, in a two-year prospective follow-up of the same cohort, Irwin and colleagues showed that the vaccine-stimulated cellular immune response to VZV was reduced in those with untreated depression, and this reduction persisted over two years. (Irwin *et al.* 2013). Other studies have found that depression is associated with a reduced vaccine-induced antibody response to hepatitis B virus (HBV) antibody response (Afsar *et al.* 2009), with similar effects for psychological stress (Kiecolt-Glaser *et al.* 1996; Vedhara *et al.* 1999; Miller *et al.* 2004; Segerstrom *et al.* 2012).

Nonetheless, it remains unknown whether depression affects the maintenance of immunity into adulthood following childhood vaccination. Childhood vaccination is critical for the prevention of infectious disease into adulthood. However, major depression is a common disorder with a lifetime prevalence of ~15% in high-income countries and ~11% in low-income countries (Kessler *et al.* 2012), which may significantly impair immunity and therefore affect public health. This study addressed this question and hypothesized that adults diagnosed with mood disorders would be less likely than non-depressed comparison controls to test seropositive for measles.

Methods

The study was approved by the Western IRB and was conducted according to the principles expressed in Declaration of Helsinki. The participants, who gave written informed consent to participate and received financial compensation, were between ages 18 and 55 years of age, and were recruited through a variety of sources including: the clinical services of the Laureate Psychiatric Clinic and Hospital (LPCH), newspaper, flyer, radio, Facebook or other media advertisements in the Tulsa metropolitan area.

Both participants with a mood disorder and non-depressed comparison controls took part in a study involving neuroimaging and immunophenotyping. As part of the immunophenotyping, measles antibody titers were obtained on 433 participants born after the introduction of the measles vaccine in 1963. The mood disorder group consisted of 82 participants with MDD in full or partial remission (rMDD), 85 with current mild, moderate or severe MDD (cMDD), and 64 with bipolar disorder type I, type II or not otherwise specified (NOS). Diagnoses were established according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) using the Structured Clinical Interview for DSM-IV-TR (SCID) administered by a trained clinical interviewer and an unstructured interview with a psychiatrist. Supplementary Table S1 details the specific DSM-IV-TR diagnostic classifications within the mood disorder cohort. Measures of depression severity such as the Montgomery-Asberg Depression Rating Scale (MADRS), lifetime number of depressive episodes, and the age of onset were also obtained as part of the clinical assessment. Non-depressed comparison controls (HC, n=202) had no personal

history of psychiatric illness as measured by the SCID. Table 1 summarizes the sample demographics.

Supplementary Table S2 summarizes comorbid medical conditions. Exclusion criteria were as follows: serious suicidal ideation or behavior; current medical conditions or concomitant medications likely to influence CNS or immunological function including significant cardiovascular, respiratory, endocrine and neurological diseases; a history of drug or alcohol abuse within 6 months or a history of drug or alcohol dependence within 1 year (DSM-IV-TR criteria).

Blood samples were collected by venipuncture into Becton-Dickinson Vacutainer tubes containing EDTA. Plasma was separated following standard laboratory protocols and stored at -80°C until testing. Seropositivity was determined for IgG antibodies against measles blind to diagnosis using a commercially available solid phase immunoassay (IBL America, www.ibl-america.com). A sample was considered seropositive if it had an optical density value of ≥ 0.5 , which is equivalent to approximately 10 international units of antibody.

We determined the relationship between diagnosis and IgG measles serostatus using multivariate logistic regression models, controlling for age, sex, and ethnicity. To maintain statistical power and since 85.7% of all participants reported Caucasian ethnicity, the ethnicity variable was reduced to Caucasian versus non-Caucasian. Results are reported as adjusted odds ratios (OR) and their respective 95% confidence interval (95% CI) along with the p value of the coefficient. Analyses were performed using R version 3.3.2 in RStudio version 1.0.136. Power analyses were performed using Gpower version 3.1.

Since both MDD groups differed from the HC group in serostatus, secondary analyses were performed within the combined MDD group (cMDD and rMDD, $n=167$) to determine the relationship between measles serostatus and (a) current use of psychotropic medication, (b) years lived with depression/self-reported lifetime number of depressive episodes, and (c) total MADRS score. To control for false positives, a Bonferroni correction was performed such that the significance threshold was set at $p<0.017$ ($0.05/3$) for these secondary analyses. The medicated subgroup reported use of psychotropic medication other than sleep aids within the 3 weeks (8 weeks for fluoxetine) prior to visit. Lifetime number of depressive episodes was reported in the psychiatric interview. “Too many to count” was coded as “99” and this accounted for 15.3% of all cases. We therefore categorized each participant as either “low” (less than or equal to three episodes) or “high” (greater than three episodes) by median split and used this binomial variable in the analyses.

Results

Participants with a mood disorder were less likely to be seropositive for measles ($p=0.015$, adjusted OR=0.53, 95% CI: 0.31–0.88; Table 2). There was no effect of sex ($p=0.376$, adjusted OR=1.30, 95% CI: 0.74–2.37), however, as expected, age was a predictor of serostatus ($p=0.014$, adjusted OR=0.97, 95% CI: 0.94–0.99). In addition, the non-Caucasian group was associated with increased odds of being seropositive ($p=0.015$, adjusted OR=3.29, 95% CI: 1.38–9.78). Within the mood disorder group, both the rMDD ($p=0.038$,

adjusted OR=0.50, 95% CI: 0.26–0.97) and the cMDD ($p=0.021$, adjusted OR=0.47, 95% CI: 0.24–0.90) groups showed decreased odds of seropositivity compared with HC (Figure 1). The likelihood of being seropositive for individuals with BD did not differ either from healthy comparison subjects ($p=0.329$), or from the cMDD ($p=0.355$) or rMDD ($p=0.449$) participants. Post hoc power analysis showed that the model was 70.2% and 78.6% powered to detect differences in the rMDD and cMDD groups, respectively, but only 24.5% powered to detect differences in the BD group.

Within the combined MDD group, there was no significant relationship between serostatus and number of previous depressive episodes ($p=0.221$, adjusted OR=1.68, 95% CI: 0.74–3.96), years lived with depression ($p=0.827$, adjusted OR=0.99, 95% CI: 0.92–1.06), or total MADRS score ($p=0.641$, adjusted OR=1.01, 95% CI: 0.98–1.04). The currently medicated MDD participants ($n=48$, Table S3) showed diminished seropositivity compared to the unmedicated MDD participants ($p=0.018$ uncorrected, adjusted OR=0.39, 95% CI: 0.18–0.85). Compared with the unmedicated MDD group, the medicated group had a significantly higher mean years lived with depression (19.1 ± 10.7 versus 12.7 ± 8.2 , Welch's $t(42.2)=2.91$, $p=0.006$). Likewise, current use of medication was associated with a high lifetime number of depressive episodes (63.2% versus 37.2%, $X^2(1)=7.17$, $p=0.007$). To test whether past use of medication predicted measles serostatus, the currently unmedicated MDD group was subdivided into those with previous use of medication ($n=61$) and those naïve to medication ($n=47$). The previously medicated group had a significantly higher mean years lived with depression (14.55 ± 9.06 years) compared to the naïve group (9.97 ± 6.07 years, Welch's $t(69.0)=-2.55$, $p=0.013$), so this was included as a covariate to control for lifelong depression severity. Past use of medication was not a significant predictor of measles seropositivity (OR=0.72, 95% CI=0.17–2.76, $p=0.638$) within the currently unmedicated MDD group.

Non-exclusionary comorbid medical illnesses were reported at a higher rate in the mood disorder group than in the HC group. Study personal categorized these reports into constitutional, ear nose throat or mouth, cardiovascular, genitourinary, respiratory, gastrointestinal, musculoskeletal, integumentary, neurological, endocrine or hematologic/lymphatic groups (see Supplementary Table S2). However, none of these categories were significant predictors of measles serostatus within the combined MDD group (all p 's > 0.1, Table S4).

Because immunization records were not available for the cohort, we attempted to determine if other variables that conceivably could be associated with a lower rate of vaccine uptake (e.g. suboptimal childhood healthcare) were associated with measles serostatus. We hypothesized that a family environment where one or both parents had a mood disorder or substance abuse problem could be related to vaccine uptake. To test this potential effect, we divided our comparison control group into those with a parental mood disorder or substance abuse problem ($n=69$) and those without ($n=86$) and found no relationship with measles seropositivity (OR=0.52, 95% CI: 0.20–1.30, $p=0.165$).

Discussion

This study examined and found support for the hypothesis that compared with HC, individuals with adolescent or adult onset depression were less likely to test seropositive for measles because of impaired maintenance of vaccine-induced immunity. There were three main results: first, relative to HC, MDD participants had half the odds of testing seropositive for measles; second, this finding was observed for both currently depressed and remitted individuals with MDD; third, medicated MDD individuals had relatively lower rates of seropositivity than unmedicated MDD subjects. Taken together, these results support the general hypothesis that depression affects the maintenance of immunity into adulthood following childhood vaccination.

This is the first study to report reduced efficacy of a vaccine administered early in childhood in participants with adolescent or adult onset MDD. This is a finding of significant clinical importance as the high lifetime prevalence of MDD may weaken population levels of immunity to measles and conceivably other infectious diseases. Globally, measles is the 14th leading cause of disability adjusted life years (DALYs) in children and adolescents (Kassebaum *et al.* 2017) and is responsible for approximately 150,000 deaths per annum (Holzmann *et al.* 2016). In the USA, there were a total of 1,558 confirmed cases of measles between January 1, 2010 and June 17, 2017, and a substantial portion (9–20%) of these cases occurred in individuals who had received at least one dose of vaccine (Centers for Disease Control and Prevention (CDC) 2012; Clemmons *et al.* 2015).

The specific mechanism underlying the impaired maintenance of MMR vaccine-induced immunity to measles in MDD remains unclear. Nevertheless, there are several pathways through which the central nervous system modulates immunity. For instance, the sympathetic nervous system (SNS) regulates activity of the immune system both directly, through innervation of the primary and secondary lymphoid organs, as well as humorally via catecholamine release (Besedovsky *et al.* 1979; Sanders 2006). Second, glucocorticoids released by the hypothalamic-pituitary-adrenal (HPA) axis play an important role in regulating the immune response to bacterial and viral infection; excess glucocorticoid release in the context of chronic stress increases susceptibility to viral infections (Cohen & Williamson 1991). Third, shorter sleep duration or sleep restriction, which is associated with reduced antibody titers after vaccination (Spiegel *et al.* 2002; Prather *et al.* 2012), may affect the relative frequency of circulating T cells, B cells, and natural killer cells (Suzuki *et al.* 2017). MDD is frequently characterized by SNS activation, hypercortisolemia, and altered distributions of circulating lymphocytes, potentially explaining why it has not only been linked with impaired vaccine response, but with other characteristics of impaired adaptive immunity such as reduced mitogen-stimulated lymphocyte proliferation, a greater susceptibility to viral infections, reactivation of latent herpesviruses, and slowed wound healing (Cohen & Williamson 1991; Blume *et al.* 2011). Thus, depression may have immunosuppressive effects in a subset of patients.

Loss of immunity to measles and other infectious agents generally occurs in the context of immunosuppression. Anti-measles antibodies and measles antibody secreting cells are decreased in HIV infected patients (Titanji *et al.* 2006). In a study of 195 children with a

variety of cancers, 27% lost humoral immunity to measles following intensive chemotherapy (Bochennek *et al.* 2014). Similarly, a loss of IgG-measles antibodies in 65% of previously vaccinated adolescent liver transplant recipients one year after surgery was reported (Kano *et al.* 2002). Other studies report a similar loss of immunity in cardiac, renal and heart-lung transplants for measles and other vaccine-related antibodies (Warmington *et al.* 2005; Rocca *et al.* 2016). Immunosuppressive therapy to prevent graft rejection includes corticosteroids and several classes of drugs that inhibit T cell activation.

As discussed above, other immunosuppressive conditions have previously been associated with a loss of humoral immunity to measles. Thus, one possible explanation for our results is that individuals who go on to develop MDD have a normal rate of seroconversion following vaccination but lose humoral immunity to measles due to the endocrine and immunological abnormalities that occur in the context of depressive episodes. Consistent with this hypothesis, Glaser *et al.* found that, compared to controls, stressed caregivers of spouses with dementia displayed normal antibody titers two weeks following injection with the pneumococcal pneumonia vaccine, but that humoral antibody concentration was significantly diminished six months post-vaccination (Glaser *et al.* 2000). Longitudinal studies of children will be required to determine if this finding extends to childhood vaccine responders who later develop depression. The fact that depression rating scale scores were not associated with serostatus and reduced seropositivity to measles was present in the rMDD as well as the cMDD group suggests that the detrimental effects of depression on immunity are not limited to the symptomatic phase of the disorder.

Depressive episodes could conceivably result in the permanent loss of antibody-secreting plasma and memory B cells. In support of this possibility, the currently medicated MDD subgroup, which had lower rates of seropositivity to measles than the unmedicated MDD subgroup, had experienced more episodes of depression and more years with depression than the unmedicated subgroup prior to our analyses. Nevertheless, recall of age of illness onset and number of depressive episodes by patients is known to be inaccurate and thus this result should be treated with caution.

There is some evidence that psychotropic medications, including selective serotonin reuptake inhibitors may have immunosuppressive effects (Gobin *et al.* 2014). Thus, an alternative explanation for the decrease in seropositivity in the medicated subgroup versus the unmedicated depressed subgroup is that exposure to antidepressant medication rather than depression *per se*, reduces immunity to measles. The effects of medication exposure versus the effects of depressive episodes cannot be definitively disambiguated in our study. However, in order to partially address this issue, we compared currently unmedicated MDD participants who were psychotropic medication-naïve (n=47) from currently unmedicated MDD participants with a past history of medication use (n=61). Controlling for number of years lived with depression, there was no significant effect of past use of medication (p=0.638) suggesting that immune suppression due to use of medication did not contribute to the loss of immunity to measles in the rMDD and cMDD groups.

Another explanation for the MDD-associated decrease in immunity to measles is that immune dysfunction is already present early in life in a subset of individuals who become

depressed in adolescence or adulthood, and that this immune dysfunction results in a reduced frequency of seroconversion to measles after vaccination. The mechanisms underlying this putative immune dysfunction are unclear although genetic factors may be relevant. HLA class I and II genotypes and single nucleotide polymorphisms (SNPs) in cytokine genes, cytokine receptor genes and the cell surface measles receptor (CD46) gene have been identified as genetic regulators of the vaccine response to measles (Kennedy *et al.* 2012; Haralambieva *et al.* 2013). Polymorphisms in one of these genes, interleukin 6 (IL-6), also have been linked with MDD (Zhang *et al.* 2016). Similarly, SNPs in the vicinity of the interferon-induced protein 44 like (IFI44L) gene have been associated with MMR vaccine-related febrile seizures and measles neutralizing antibody response (Feenstra *et al.* 2014; Haralambieva *et al.* 2017). The IFI44L region also has been associated with risk for BD and schizophrenia in a combined GWAS study (Ruderfer *et al.* 2014).

The rate of seropositivity in the bipolar disorder group was intermediate between that of the HC and MDD groups (Table 1) and did not differ significantly from either of these groups. However, these negative results in the bipolar disorder group may be due to reduced statistical power given the smaller sample size in the bipolar disorder group versus the MDD groups. Thus, larger studies are needed to determine if bipolar disorder also is associated with a reduction in measles seropositivity.

This study has several limitations. First, immunization records were not available from participants and therefore it is theoretically possible that the MDD participants were less likely to be vaccinated than the HCs. However, this possibility is mitigated by the fact that schools require records of MMR vaccination prior to admission and thus vaccination rates are relatively high (currently 92–94% (Seither *et al.* 2016)), especially in the generation of individuals who grew-up prior to the erroneous concerns about the link between autism and vaccination. Moreover, to further address the possibility that individuals who later developed depression were less likely to have been vaccinated, we compared measles serostatus in the healthy controls with no family history of depression to those of the healthy controls with at least one parent with a mood disorder or substance abuse problem. Our rationale for this analysis was that if psychiatric illness in the parents of a child had any significant bearing on the likelihood that the child would receive vaccinations, then those healthy individuals with a family history of a mood disorder would be less likely to test seropositive for measles than healthy controls with no family history of depression. Parental history of mood disorder or substance abuse did not significantly decrease the odds of testing seropositive for measles ($p=0.165$).

The second limitation of the study is that because post-vaccine antibody titers were not available, we were unable to differentiate between the early-life immune dysfunction and adulthood immune suppression explanations for our results. Third, although serious co-morbid medical disorders such as cardiovascular disease, current cancer, multiple sclerosis, and HIV were exclusionary, the mood disorder group did have a higher rate of medical illness than the HCs. Thus, it is theoretically possible that the difference in serostatus between the groups may be related to these co-morbid illnesses rather than depression *per se*. Nevertheless, as shown in Table S4, none of the categories of medical illnesses were significantly associated with measles serostatus in the MDD group. Fourth, it remains

unclear to what extent vaccine-induced antibodies against the measles virus correlate with protection against either clinical or subclinical infection. However, at least in children, individuals with high antibody levels appear protected against measles, while individuals with low or intermediate titers are more susceptible to clinical or mild infection (Chen *et al.* 1990)

By measuring antibodies to viruses such as rubella and polio, future studies could evaluate whether the MDD-associated reduction in seropositivity to measles reported here is specific to measles or whether it extends to other pathogens. Second, in the absence of prospective data, re-vaccination of fully remitted individuals who are seronegative for measles (or other relevant viruses) may help to parse out the effects of genetic factors versus acute depressive episodes on vaccine response.

In sum, we found that MDD is associated with significantly lower rates of seropositivity for measles compared to healthy controls. These lower levels of antibodies may be a significant risk factor for susceptibility to measles infection despite previous measles immunization. Our findings may have important implications for public health as the high lifetime prevalence of MDD may weaken population levels of immunity to measles (and potentially other infectious diseases) with a subsequent increase in the risk of transmission of measles (and potentially other viruses) within the population. It is conceivable that health care providers could mitigate this problem by prioritizing depressed populations for antibody screening and re-vaccination efforts.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank all the research participants and wish to acknowledge the contributions of Brenda Davis, Debbie Neal, Chibing Tan, and Ashlee Rempel from the laboratory of TKT at the University of Oklahoma Integrative Immunology Center towards the transport, processing and handling of all blood samples. We also thank Dr. Henry Yeh at the Laureate Institute for Brain Research for his advice on the statistical analyses.

Funding

This work was supported by the Laureate Institute for Brain Research. JS also received support from the Brain and Behavior Research Foundation and the National Institutes of Health (P20GM121312).

Dr. Paulus has received royalties for an article about methamphetamine use disorder from UpToDate.

References

- Afsar B, Elsurur R, Eyileten T, Yilmaz MI, Caglar K (2009). Antibody response following hepatitis B vaccination in dialysis patients: does depression and life quality matter? *Vaccine* 27, 5865–5869. [PubMed: 19654067]
- Besedovsky HO, del Rey A, Sorkin E, Da Prada M, Keller HH (1979). Immunoregulation mediated by the sympathetic nervous system. *Cellular immunology* 48, 346–355. [PubMed: 389444]
- Blume J, Douglas SD, Evans DL (2011). Immune suppression and immune activation in depression. *Brain, behavior, and immunity* 25, 221–229.

- Bochennek K, Allwinn R, Langer R, Becker M, Keppler OT, Klingebiel T, Lehnbecher T (2014). Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer. *Vaccine* 32, 3357–3361. [PubMed: 24793952]
- Centers for Disease Control and Prevention (CDC) (2012). Measles - United States, 2011. *MMWR. Morbidity and mortality weekly report* 61, 253–257. [PubMed: 22513526]
- Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA (1990). Measles antibody: reevaluation of protective titers. *The Journal of infectious diseases* 162, 1036–1042. [PubMed: 2230231]
- Clemmons NS, Gastanaduy PA, Fiebelkorn AP, Redd SB, Wallace GS, Centers for Disease Control and Prevention (CDC) (2015). Measles - United States, January 4–April 2, 2015. *MMWR. Morbidity and mortality weekly report* 64, 373–376. [PubMed: 25879894]
- Cohen S, Williamson GM (1991). Stress and infectious disease in humans. *Psychological bulletin* 109, 5–24. [PubMed: 2006229]
- Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H (2008). Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. *The Journal of infectious diseases* 197, 950–956. [PubMed: 18419470]
- Dine MS, Hutchins SS, Thomas A, Williams I, Bellini WJ, Redd SC (2004). Persistence of vaccine-induced antibody to measles 26–33 years after vaccination. *The Journal of infectious diseases* 189 Suppl 1, S123–30. [PubMed: 15106101]
- Feenstra B, Pasternak B, Geller F, Carstensen L, Wang T, Huang F, Eitson JL, Hollegaard MV, Svanström H, Vestergaard M, Hougaard DM, Schoggins JW, Jan LY, Melbye M, Hviid A (2014). Common variants associated with general and MMR vaccine-related febrile seizures. *Nature genetics* 46, 1274–1282. [PubMed: 25344690]
- Fiebelkorn AP, Redd SB, Gallagher K, Rota PA, Rota J, Bellini W, Seward J (2010). Measles in the United States during the postelimination era. *The Journal of infectious diseases* 202, 1520–1528. [PubMed: 20929352]
- Glaser R, Sheridan J, Malarkey WB, MacCallum RC, Kiecolt-Glaser JK (2000). Chronic stress modulates the immune response to a pneumococcal pneumonia vaccine. *Psychosomatic medicine* 62, 804–807. [PubMed: 11139000]
- Gobin V, Van Steendam K, Denys D, Deforce D (2014). Selective serotonin reuptake inhibitors as a novel class of immunosuppressants. *International immunopharmacology* 20, 148–156. [PubMed: 24613205]
- Haralambieva IH, Ovsyannikova IG, Kennedy RB, Larrabee BR, Zimmermann MT, Grill DE, Schaid DJ, Poland GA (2017). Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing antibody response to measles vaccine. *Human genetics* 136, 421–435. [PubMed: 28289848]
- Haralambieva IH, Ovsyannikova IG, Pankratz VS, Kennedy RB, Jacobson RM, Poland GA (2013). The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. *Expert review of vaccines* 12, 57–70. [PubMed: 23256739]
- Holzmann H, Hengel H, Tenbusch M, Doerr HW (2016). Eradication of measles: remaining challenges. *Medical microbiology and immunology* 205, 201–208. [PubMed: 26935826]
- Irwin MR, Levin MJ, Carrillo C, Olmstead R, Lucko A, Lang N, Caulfield MJ, Weinberg A, Chan ISF, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Johnson G, Oxman MN (2011). Major depressive disorder and immunity to varicella-zoster virus in the elderly. *Brain, behavior, and immunity* 25, 759–766.
- Irwin MR, Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, Carrillo C, Stanley HA, Caulfield MJ, Weinberg A, Chan ISF, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Zhang JH, Johnson G, Oxman MN (2013). Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* 56, 1085–1093. [PubMed: 23413415]

- Kano H, Mizuta K, Sakakihara Y, Kato H, Miki Y, Shibuya N, Saito M, Narita M, Kawarasaki H, Igarashi T, Hashizume K, Iwata T (2002). Efficacy and safety of immunization for pre- and post-liver transplant children. *Transplantation* 74, 543–550. [PubMed: 12352917]
- Kassebaum NJ, Smith AGC, Bernabé E, Fleming TD, Reynolds AE, Vos T, Murray CJL, Marcenes W, GBD 2015 Oral Health Collaborators (2017). Global, Regional, and National Prevalence, Incidence, and Disability-Adjusted Life Years for Oral Conditions for 195 Countries, 1990–2015: A Systematic Analysis for the Global Burden of Diseases, Injuries, and Risk Factors. *Journal of dental research* 96, 380–387. [PubMed: 28792274]
- Kennedy RB, Ovsyannikova IG, Haralambieva IH, O’Byrne MM, Jacobson RM, Pankratz VS, Poland GA (2012). Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes. *Vaccine* 30, 2159–2167. [PubMed: 22265947]
- Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U (2012). Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. *International journal of methods in psychiatric research* 21, 169–184. [PubMed: 22865617]
- Kiecolt-Glaser JK, Glaser R, Gravenstein S, Malarkey WB, Sheridan J (1996). Chronic stress alters the immune response to influenza virus vaccine in older adults. *Proceedings of the National Academy of Sciences of the United States of America* 93, 3043–3047. [PubMed: 8610165]
- McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease Control and Prevention (2013). Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control* 62, 1–34.
- Measles Cases and Outbreaks (n.d.). Center for Disease Control and Prevention
- Measles Fact Sheet (2017). World Health Organization
- Miller GE, Cohen S, Pressman S, Barkin A, Rabin BS, Treanor JJ (2004). Psychological stress and antibody response to influenza vaccination: when is the critical period for stress, and how does it get inside the body? *Psychosomatic medicine* 66, 215–223. [PubMed: 15039506]
- Mossong J, Nokes DJ, Edmunds WJ, Cox MJ, Ratnam S, Muller CP (1999). Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. *American journal of epidemiology* 150, 1238–1249. [PubMed: 10588085]
- Prather AA, Hall M, Fury JM, Ross DC, Muldoon MF, Cohen S, Marsland AL (2012). Sleep and antibody response to hepatitis B vaccination. *Sleep* 35, 1063–1069. [PubMed: 22851802]
- Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE (2004). Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. *The Journal of infectious diseases* 189 Suppl 1, S116–22. [PubMed: 15106100]
- Rocca S, Santilli V, Cotugno N, Concato C, Manno EC, Nocentini G, Macchiarulo G, Cancrini C, Finocchi A, Guzzo I, Dello Strologo L, Palma P (2016). Waning of vaccine-induced immunity to measles in kidney transplanted children. *Medicine* 95, e4738. [PubMed: 27631222]
- Ruderfer DM, Fanous AH, Ripke S, McQuillin A, Amdur RL, Schizophrenia Working Group of Psychiatric Genomics Consortium, Bipolar Disorder Working Group of Psychiatric Genomics Consortium, Cross-Disorder Working Group of Psychiatric Genomics Consortium, Gejman PV, O’Donovan MC, Andreassen OA, Djurovic S, Hultman CM, Kelsoe JR, Jamain S, Landén M, Leboyer M, Nimgaonkar V, Nurnberger J, Smoller JW, Craddock N, Corvin A, Sullivan PF, Holmans P, Sklar P, Kendler KS (2014). Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. *Molecular psychiatry* 19, 1017–1024. [PubMed: 24280982]
- Sanders VM (2006). Interdisciplinary research: noradrenergic regulation of adaptive immunity. *Brain, behavior, and immunity* 20, 1–8.
- Segerstrom SC, Hardy JK, Evans DR, Greenberg RN (2012). Vulnerability, distress, and immune response to vaccination in older adults. *Brain, behavior, and immunity* 26, 747–753.
- Seither R, Calhoun K, Mellerson J, Knighton CL, Street E, Dietz V, Underwood JM (2016). Vaccination Coverage Among Children in Kindergarten - United States, 2015–16 School Year. *MMWR. Morbidity and mortality weekly report* 65, 1057–1064. [PubMed: 27711037]

- Spiegel K, Sheridan JF, Van Cauter E (2002). Effect of sleep deprivation on response to immunization. *JAMA: the journal of the American Medical Association* 288, 1471–1472.
- Suzuki H, Savitz J, Kent Teague T, Gandhapudi SK, Tan C, Misaki M, McKinney BA, Irwin MR, Drevets WC, Bodurka J (2017). Altered populations of natural killer cells, cytotoxic T lymphocytes, and regulatory T cells in major depressive disorder: Association with sleep disturbance. *Brain, behavior, and immunity*
- Titanji K, De Milito A, Cagigi A, Thorstensson R, Grützmeier S, Atlas A, Hejdeman B, Kroon FP, Lopalco L, Nilsson A, Chiodi F (2006). Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. *Blood* 108, 1580–1587. [PubMed: 16645169]
- Vedhara K, Cox NK, Wilcock GK, Perks P, Hunt M, Anderson S, Lightman SL, Shanks NM (1999). Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination. *The Lancet* 353, 627–631.
- Warmington L, Lee BE, Robinson JL (2005). Loss of antibodies to measles and varicella following solid organ transplantation in children. *Pediatric transplantation* 9, 311–314. [PubMed: 15910386]
- Zhang C, Wu Z, Zhao G, Wang F, Fang Y (2016). Identification of IL6 as a susceptibility gene for major depressive disorder. *Scientific reports* 6, 31264. [PubMed: 27502736]

Figure 1.

Bar chart showing the percentage of participants seropositive for measles in each diagnostic group. Both the rMDD and cMDD groups, individually, as well as the combined mood disorder group (rMDD, cMDD, and BD) had lower odds of being seropositive for measles than the HC group, controlling for age, sex and ethnicity.

* logistic regression coefficient $p < 0.05$

HC = healthy control, rMDD = major depressive disorder in remission; cMDD = current major depressive disorder; BD = bipolar disorder.

Table 1.

Cohort data

	HC	BD	rMDD	cMDD	Test for Independence	
N	202	64	82	85	Test Statistic	p
Mean Age (SD)	30.6 (9.1)	33.2 (8.3)	32.0 (10.2)	34.6 (9.4)	F(3) = 4.30	0.005 ^a
% Female	67.8	78.1	72.0	81.2	X ² = 6.48	0.091
Mean MADRS (SD)	1.5 (2.3)	23.3 (11.4)	11.6 (10.0)	25.6 (9.1)	F(3) = 266.7	<0.001 ^a
Mean Age of Onset (SD)	NA	16.6 (5.6)	19.2 (8.6)	17.9 (7.0)	F(2) = 1.46	0.236
% Medicated ^b	0.0	67.2	19.5	37.6	X ² = 34.39	<0.001 ^a
Race & Ethnicity – n (%)						
Caucasian	177 (87.6)	50 (78.1)	71 (86.6)	73 (85.9)	X ² = 3.66	0.301
Native American	14 (6.9)	15 (23.4)	8 (9.8)	16 (18.8)	X ² = 16.67	0.001 ^a
African American	16 (7.9)	2 (3.1)	4 (4.9)	4 (4.7)	X ² = 2.69	0.442
Hispanic	6 (3.0)	7 (10.9)	1 (1.2)	7 (8.2)	X ² = 11.14	0.011 ^a
Asian	4 (2.0)	1 (1.6)	1 (1.2)	3 (3.5)	X ² = 1.27	0.736
Native Hawaiian/ Pacific Islander	2 (1.0)	1 (1.6)	0 (0.0)	2 (2.4)	X ² = 2.17	0.538

HC = healthy control; BD = bipolar disorder; rMDD = remitted major depressive disorder; cMDD = current major depressive disorder; MADRS = Montgomery-Asberg Depression Rating Scale

^a – significant at $\alpha = 0.05$

^b – Use of psychotropic drugs other than sleep aids within 3 weeks (8 for fluoxetine) prior to visit.

Table 2.

Logistic regression results predicting measles seropositivity controlling for age, sex and ethnicity.

	Measles Serostatus		Logistic Regression		
	Positive (%)	Negative (%)	OR	95% CI	p
HC	175 (86.6)	27 (13.4)	-	-	-
Mood Disorder (combined)	176 (76.2)	55 (23.8)	0.53 ^a	0.31–0.88	0.015
BD	52 (81.2)	12 (18.8)	0.68 ^a	0.32–1.51	0.329
rMDD	62 (75.6)	20 (24.4)	0.50 ^a	0.26–0.97	0.038
cMDD	62 (72.9)	23 (27.1)	0.47 ^a	0.24–0.90	0.021
Major Depressive Disorder^c					
Unmedicated	95 (79.8)	24 (20.2)	-	-	-
Medicated^d	29 (60.4)	19 (39.6)	0.39 ^b	0.18–0.85	0.018

HC = healthy control; BD = bipolar disorder; rMDD = remitted major depressive disorder; cMDD = current major depressive disorder

^a – Compared to HC

^b – Compared to MDD, Unmedicated

^c – rMDD + cMDD, n = 167

^d – Use of psychotropic drugs other than sleep aids within 3 weeks (8 for fluoxetine) prior to visit.